INSUBCONTINENT EXCLUSIVE:
NEW DELHI: Aurobindo Pharma fell as much as 7.45 per cent on early Tuesday on muted quarterly numbers
The drug firm on Monday reported a marginal decline in its net profit at Rs 528.5 crore for the fourth quarter to March 2018
Its net profit read Rs 532.5 crore in the previous fiscal
Revenue from operations, however, rose to Rs 4,049.1 crore for January-March, compared with Rs 3,641.6 crore earlier, Aurobindo Pharma said
in a regulatory filing.
For 2017-18, the company posted a net profit of Rs 2,423.2 crore, up 5.3 per cent, from Rs 2,301.7 crore in
2016-17.
"The company has reported a healthy growth in revenues and profitability in FY18, led by improvement in most of the markets,"
Aurobindo Pharma Managing Director N Govindarajan said.
The company continues to ramp up investment in differentiated and specialty product
portfolio, Govindarajan added.
At 10:09 am, shares of the company were trading at Rs 583.55 on the BSE, down 3.56 per cent
